Search Results - bivalent

3 Results

Sort By:

Bivalent, Dual Specific Anti-CD22 Anti-CD19 Chimeric Antigen Receptors (CARs)

Abstract: Chimeric antigen receptors (CARs) combine an antibody-based binding domain (and single chain fragment variable region, scFv) with T cell receptor signaling domains (CD3 zeta with a costimulatory domain, typically CD28 or 41BB). When T cells express CARs, they are activated in a major histocompatibility complex- (MHC) independent manner to...

Published: 4/8/2024 | Inventor(s): Terry Fry, Crystal Mackall, Rimas Orentas, Haiying Qin, Waleed Haso

Keywords(s): Acute Lymphoblastic Leukemia, ALL, BISPECIFIC, Bivalent, CAR, CD19, CD22, Diffuse Large B-Cell Lymphoma, DLBCL, Dual-Specific Chimeric Antigen Receptors, Fry, Oncology, Pediatric Leukemia, Pediatric Lymphoma

Category(s): Collaboration Sought > Licensing, Application > Therapeutics, Collaboration Sought > Collaboration, TherapeuticArea > Oncology

Multivalent Vaccines for Rabies Virus and Filoviruses

No vaccine candidates against Ebola virus (EBOV) or Marburg virus (MARV) are nearing licensure and the need to develop a safe and efficacious vaccine against filoviruses continues. Whereas several preclinical vaccine candidates against EBOV or MARV exist, their further development is a major challenge based on safety concerns, pre-existing vector immunity,...

Published: 7/25/2024 | Inventor(s): Jason Paragas, Reed Johnson, Peter Jahrling, Joseph Blaney

Keywords(s): Against, Bivalent, Confer, DA4BXX, DA4XXX, DAXXXX, DC5BXX, DC5XXX, DC6XXX, DCXXXX, DDXXXX, Dual, DXXXXX, Ebola, Ebola virus disease, INACTIVATED, Live-Attenuated, Marburg hemorrhagic fever, Protection, rabies, That, UAXXXX, vaccines, Viruses

Category(s): Collaboration Sought > Licensing, Application > Vaccines, TherapeuticArea > Infectious Disease, Application > Diagnostics, Application > Research Materials, TherapeuticArea > Rare / Neglected Diseases

Methods for Expression and Purification of Immunotoxins

The invention concerns immunotoxins and methods of making the immunotoxins. Targeting of the immunotoxins occurs via an antibody that is specific to T cells. This allows the specific ablation of malignant T cells and resting T cells. The transient ablation of resting T cells can "reset" the immune system by accentuating tolerizing responses. As...

Published: 7/25/2024 | Inventor(s): David Neville

Keywords(s): Aplastic anemia, Are, Bivalent, CB6XXX, CBXXXX, COMPLEX, CXXXXX, ESSENTIAL, Graft versus host disease, IB3XXX, IBXXXX, Immunotoxin, IXXXXX, LOW, lymphoma, Media, PASTORIS, PICHIA, production, temperature

Category(s): Collaboration Sought > Licensing, Application > Research Materials, TherapeuticArea > Immunology, Application > Diagnostics, Application > Therapeutics, TherapeuticArea > Oncology